$ZYME

$28.37 +$0.15 (0.53%) Close

$ZYME Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Company Executives

$ZYME Management Team

Mr. Kenneth Galbraith

Chairman of the Board

Chief Executive Officer

Age 59

Compensation -

Sex Male

Mr. Neil Klompas

President

Chief Operating Officer

Age 50

Compensation $1.900M USD

Sex Male

Dr. Christopher Astle

Chief Financial Officer

Senior Vice President

Age 42

Compensation -

Sex Male

Dr. Paul Moore

Chief Scientific Officer

Age -

Compensation -

Sex Male

Dr. Neil Josephson

Chief Medical Officer

Age 61

Compensation $3.548M USD

Sex Male

Name / Title	Age	Compensation	Sex
Mr. Kenneth Galbraith Chairman of the Board Chief Executive Officer	59	-	Male
Mr. Neil Klompas President Chief Operating Officer	50	$1.900M USD	Male
Dr. Christopher Astle Chief Financial Officer Senior Vice President	42	-	Male
Dr. Paul Moore Chief Scientific Officer	-	-	Male
Dr. Neil Josephson Chief Medical Officer	61	$3.548M USD	Male

Board of Directors

From the proxy statement filed Oct 26, 2026

Directors

serving now

Independent

6 of 7

stated in the proxy

Average tenure

2.4 years

from year joined

CEO also chairs the board

Yes

Kenneth Galbraith

Director	Age	On board	Independent	Committees	Other public boards	2025 pay
Brian N. Cherry	52	2026 0 years	Independent	Audit	Atara Biotherapeutics	Not stated
Gregory A. Ciongoli	51	2025 1 year	Independent	Nominating and Corporate Governance · Chair	REGENXBIO Inc.	Not stated
Oleg Nodelman	49	2025 1 year	Independent	Compensation	Galapagos NV	Not stated
Carlos Campoy	62	2023 3 years	Independent	Audit · Chair	None stated	$65,000
Alessandra Cesano	66	2024 2 years	Independent	Nominating and Corporate Governance	Puma Biotechnology, Inc.	$51,875
Kenneth Galbraith Board chair, CEO	64	2022 4 years	Not independent	None stated	None stated	Paid as CEO
Kelvin Neu	52	2020 6 years	Independent	None stated	None stated	Not stated

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

No related-party transactions disclosed

The proxy filed Oct 26, 2026 states there were none.

Read it in the proxy

Comments

Company Executives

$ZYME Management Team

Mr. Kenneth Galbraith

Mr. Neil Klompas

Dr. Christopher Astle

Dr. Paul Moore

Dr. Neil Josephson

Board of Directors

Related-party transactions

No related-party transactions disclosed